Oppenheimer Asset Management Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 11.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 698,178 shares of the biopharmaceutical company’s stock after purchasing an additional 69,202 shares during the quarter. Pfizer comprises about 0.6% of Oppenheimer Asset Management Inc.’s holdings, making the stock its 25th largest holding. Oppenheimer Asset Management Inc.’s holdings in Pfizer were worth $24,924,000 as of its most recent filing with the SEC.
Several other large investors also recently bought and sold shares of the stock. Peregrine Asset Advisers Inc. increased its holdings in shares of Pfizer by 0.5% in the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 35 shares during the last quarter. Northwest Quadrant Wealth Management LLC grew its position in Pfizer by 0.8% in the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 50 shares during the period. Stone House Investment Management LLC grew its position in Pfizer by 1.0% in the second quarter. Stone House Investment Management LLC now owns 7,236 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 72 shares during the period. Highland Private Wealth Management grew its position in Pfizer by 0.8% in the second quarter. Highland Private Wealth Management now owns 9,047 shares of the biopharmaceutical company’s stock worth $304,000 after acquiring an additional 76 shares during the period. Finally, Autus Asset Management LLC grew its position in Pfizer by 1.2% in the second quarter. Autus Asset Management LLC now owns 6,681 shares of the biopharmaceutical company’s stock worth $225,000 after acquiring an additional 78 shares during the period. 70.12% of the stock is owned by hedge funds and other institutional investors.
Several brokerages recently weighed in on PFE. BMO Capital Markets set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Thursday, February 15th. Berenberg Bank set a $36.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, January 30th. UBS Group set a $42.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Leerink Swann increased their price objective on Pfizer from $35.00 to $38.00 and gave the stock a “market perform” rating in a research report on Wednesday, January 31st. Finally, Societe Generale set a $40.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $39.45.
Pfizer Inc. (NYSE:PFE) opened at $36.26 on Friday. Pfizer Inc. has a 52-week low of $31.67 and a 52-week high of $39.43. The company has a market capitalization of $216,140.00, a price-to-earnings ratio of 20.72, a PEG ratio of 2.02 and a beta of 0.94. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The business had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. During the same period last year, the business posted $0.47 earnings per share. The company’s quarterly revenue was up .6% on a year-over-year basis. equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a $0.34 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a dividend yield of 3.75%. The ex-dividend date is Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is presently 77.71%.
Pfizer announced that its Board of Directors has initiated a stock repurchase plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s management believes its shares are undervalued.
In other news, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the sale, the insider now directly owns 103,458 shares in the company, valued at $3,827,946. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the sale, the executive vice president now owns 46,963 shares in the company, valued at $1,740,918.41. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Oppenheimer Asset Management Inc. Buys 69,202 Shares of Pfizer Inc. (PFE)” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/02/24/oppenheimer-asset-management-inc-buys-69202-shares-of-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.